103.4K XNAS Volume
XNAS 21 Mar, 2025 2:35 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Patrick Fabbio | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 23,500 | 45,500 (0%) | 0% | 0 | Common Stock | |
| Patrick Fabbio | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| Jesse Shefferman | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 387,000 | 387,000 | - | - | Stock Option (Right to Buy) | |
| Jesse Shefferman | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 65,000 | 994,022 (17%) | 1% | 0 | Common Stock | |
| Jacqueline Zummo | Chf Scientific Operations Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 146,000 | 146,000 | - | - | Stock Option (Right to Buy) | |
| Jacqueline Zummo | Chf Scientific Operations Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 24,500 | 126,639 (2%) | 0% | 0 | Common Stock | |
| Hannah Fry | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 9,500 | 38,942 (0%) | 0% | 0 | Common Stock | |
| Hannah Fry | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Patrick Fabbio | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.76 per share. | 21 Jan 2025 | 3,061 | 18,939 (0%) | 0% | 4.8 | 14,570 | Common Stock |
| Jesse Shefferman | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.76 per share. | 21 Jan 2025 | 15,469 | 913,553 (15%) | 0% | 4.8 | 73,632 | Common Stock |
| Jacqueline Zummo | Chf Scientific Operations Off | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.76 per share. | 21 Jan 2025 | 6,554 | 95,585 (1%) | 0% | 4.8 | 31,197 | Common Stock |
| Hannah Fry | VP, Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.76 per share. | 21 Jan 2025 | 2,130 | 27,312 (0%) | 0% | 4.8 | 10,139 | Common Stock |
| Jesse Shefferman | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.14 per share. | 03 Jan 2025 | 6,479 | 929,022 (15%) | 0% | 6.1 | 39,781 | Common Stock |
| Jacqueline Zummo | Chf Scientific Operations Off | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.14 per share. | 03 Jan 2025 | 2,157 | 102,139 (1%) | 0% | 6.1 | 13,244 | Common Stock |
| Hannah Fry | VP, Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.14 per share. | 03 Jan 2025 | 394 | 29,442 (0%) | 0% | 6.1 | 2,419 | Common Stock |
| Jesse Shefferman | Director, CEO and President | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Aug 2024 | 3,300 | 935,501 (16%) | 0% | 0 | Common Stock | |
| Jesse Shefferman | Director, CEO and President | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Aug 2024 | 5,263 | 938,801 (16%) | 0% | 0 | Common Stock | |
| Gregory P. Sargen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Luke M. Beshar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Roger J. Garceau | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Barry P. Flannelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Jane Huang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Michael Edward Solomon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Hannah Fry | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 8,000 | 30,740 (0%) | 0% | 0 | Common Stock | |
| Shefferman Jesse | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 59,000 | 951,867 (16%) | 1% | 0 | Common Stock | |
| Fabbio Patrick | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 22,000 | 22,000 (0%) | 0% | 0 | Common Stock | |
| Fry Hannah | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 46,000 | 46,000 | - | - | Stock Option (Right to Buy) | |
| Shefferman Jesse | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.91 per share. | 19 Jan 2024 | 7,803 | 944,064 (16%) | 0% | 1.9 | 14,904 | Common Stock |
| Shefferman Jesse | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 357,000 | 357,000 | - | - | Stock Option (Right to Buy) | |
| Jacqueline Zummo | Chf Scientific Operations Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 137,000 | 137,000 | - | - | Stock Option (Right to Buy) | |
| Jacqueline Zummo | Chf Scientific Operations Off | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.91 per share. | 19 Jan 2024 | 3,049 | 104,296 (1%) | 0% | 1.9 | 5,824 | Common Stock |
| Jathin Bandari | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.91 per share. | 19 Jan 2024 | 2,879 | 56,704 (0%) | 0% | 1.9 | 5,499 | Common Stock |
| Zummo Jacqueline | Chf Scientific Operations Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 23,000 | 107,345 (1%) | 0% | 0 | Common Stock | |
| Bandari Jathin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 137,000 | 137,000 | - | - | Stock Option (Right to Buy) | |
| Bandari Jathin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 23,000 | 59,583 (1%) | 0% | 0 | Common Stock | |
| Patrick Fabbio | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 131,000 | 131,000 | - | - | Stock Option (Right to Buy) | |
| Fry Hannah | VP, Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.91 per share. | 19 Jan 2024 | 904 | 29,836 (0%) | 0% | 1.9 | 1,727 | Common Stock |
| Jathin Bandari | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.39 per share. | 10 Jan 2024 | 1,877 | 36,583 (0%) | 0% | 2.4 | 4,486 | Common Stock |
| Shefferman Jesse | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.39 per share. | 10 Jan 2024 | 5,746 | 892,867 (15%) | 0% | 2.4 | 13,733 | Common Stock |
| Jacqueline Zummo | Chf Scientific Operations Off | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.39 per share. | 10 Jan 2024 | 5,229 | 84,345 (1%) | 0% | 2.4 | 12,497 | Common Stock |
| Zummo Jacqueline | Chf Scientific Operations Off | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 03 Jan 2024 | 1,899 | 89,574 (1%) | 0% | 2.2 | 4,121 | Common Stock |
| Shefferman Jesse | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 03 Jan 2024 | 5,840 | 898,613 (15%) | 0% | 2.2 | 12,673 | Common Stock |
| Fry Hannah | VP, Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 03 Jan 2024 | 324 | 22,740 (0%) | 0% | 2.2 | 703 | Common Stock |
| Hannah Fry | VP, Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.56 per share. | 17 Jul 2023 | 10,075 | 23,064 (0%) | 0% | 2.6 | 25,792 | Common Stock |
| Jathin Bandari | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.46 per share. | 03 Jul 2023 | 682 | 38,460 (0%) | 0% | 2.5 | 1,678 | Common Stock |
| Gregory P. Sargen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Luke M. Beshar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Roger J. Garceau | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Barry P. Flannelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Jane Huang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Michael Edward Solomon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Patrick Fabbio | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Jesse Shefferman | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 307,500 | 307,500 | - | - | Stock Option (Right to Buy) | |
| Jesse Shefferman | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 51,300 | 918,282 (15%) | 0% | 0 | Common Stock | |
| Jacqueline Zummo | Chf Scientific Operations Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 19,900 | 91,473 (1%) | 0% | 0 | Common Stock | |
| Jacqueline Zummo | Chf Scientific Operations Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 119,300 | 119,300 | - | - | Stock Option (Right to Buy) | |
| Jathin Bandari | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 20,700 | 39,142 (0%) | 0% | 0 | Common Stock | |
| Jathin Bandari | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 124,400 | 124,400 | - | - | Stock Option (Right to Buy) | |
| Hannah Fry | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 5,900 | 33,139 (0%) | 0% | 0 | Common Stock | |
| Hannah Fry | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 35,400 | 35,400 | - | - | Stock Option (Right to Buy) | |
| Jesse Shefferman | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.00 per share. | 10 Jan 2023 | 5,855 | 866,982 (14%) | 0% | 3 | 17,565 | Common Stock |
| Jacqueline Zummo | Chf Scientific Operations Off | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.00 per share. | 10 Jan 2023 | 5,225 | 71,573 (1%) | 0% | 3 | 15,675 | Common Stock |
| Jathin Bandari | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.00 per share. | 10 Jan 2023 | 1,876 | 18,442 (0%) | 0% | 3 | 5,628 | Common Stock |
| Jesse Shefferman | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.80 per share. | 03 Jan 2023 | 6,604 | 872,837 (14%) | 0% | 2.8 | 18,491 | Common Stock |
| Jacqueline Zummo | Chf Scientific Operations Off | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.80 per share. | 03 Jan 2023 | 2,159 | 76,798 (1%) | 0% | 2.8 | 6,045 | Common Stock |
| Hannah Fry | VP, Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.80 per share. | 03 Jan 2023 | 361 | 27,239 (0%) | 0% | 2.8 | 1,011 | Common Stock |
| Jesse Shefferman | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 3.84 per share. | 11 Aug 2022 | 9,065 | 879,441 (15%) | 0% | 3.8 | 34,810 | Common Stock |
| Hannah Fry | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2022 | 25,000 | 27,600 (0%) | 0% | 0 | Common Stock | |
| Blaine Davis | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.13 per share. | 15 Jul 2022 | 5,081 | 20,662 (0%) | 0% | 3.1 | 15,904 | Common Stock |
| Jathin Bandari | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.22 per share. | 01 Jul 2022 | 682 | 20,318 (0%) | 0% | 3.2 | 2,196 | Common Stock |
| Luke M. Beshar | Director | Purchase of securities on an exchange or from another person at price $ 3.10 per share. | 30 Jun 2022 | 10,000 | 198,000 (3%) | 0% | 3.1 | 31,000 | Common Stock |
| Gregory P. Sargen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Luke M. Beshar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Roger J. Garceau | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Barry P. Flannelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Jane Huang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Michael Edward Solomon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Luke M. Beshar | Director | Purchase of securities on an exchange or from another person at price $ 4.25 per share. | 14 Mar 2022 | 10,000 | 188,000 (3%) | 0% | 4.3 | 42,500 | Common Stock |
| Luke M. Beshar | Director | Purchase of securities on an exchange or from another person at price $ 4.46 per share. | 10 Mar 2022 | 10,000 | 178,000 (3%) | 0% | 4.5 | 44,555 | Common Stock |
| Jesse Shefferman | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.27 per share. | 10 Jan 2022 | 5,080 | 872,425 (14%) | 0% | 6.3 | 31,852 | Common Stock |
| Jacqueline Zummo | Chf Scientific Operations Off | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.27 per share. | 10 Jan 2022 | 4,603 | 78,957 (1%) | 0% | 6.3 | 28,861 | Common Stock |
| Jesse Shefferman | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 253,500 | 253,500 | - | - | Stock Option (Right to Buy) | |
| Jesse Shefferman | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 42,300 | 877,505 (15%) | 0% | 0 | Common Stock | |
| Jacqueline Zummo | Chf Scientific Operations Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 84,800 | 84,800 | - | - | Stock Option (Right to Buy) | |
| Jacqueline Zummo | Chf Scientific Operations Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 14,100 | 83,560 (1%) | 0% | 0 | Common Stock | |
| Blaine Davis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 84,800 | 84,800 | - | - | Stock Option (Right to Buy) | |
| Blaine Davis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 14,100 | 15,581 (0%) | 0% | 0 | Common Stock | |
| Martin Sebastian Olivo | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 10.08 per share. | 10 Jun 2021 | 4,959 | 9,410 (0%) | 0% | 10.1 | 49,987 | Common Stock |
| Martin Sebastian Olivo | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 10.13 per share. | 10 Jun 2021 | 4,934 | 14,344 (0%) | 0% | 10.1 | 49,981 | Common Stock |
| Gregory P. Sargen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Luke M. Beshar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Roger J. Garceau | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Barry P. Flannelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Jane Huang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Jane Huang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Michael Edward Solomon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Martin Sebastian Olivo | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2021 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 3,750 | 21,750 | - | - | Stock Option (Right to Buy) | |
| Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Jesse Shefferman | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 202,000 | 202,000 | - | - | Stock Option (Right to Buy) | |
| Jacqueline Zummo | Chf Scientific Operations Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Blaine Davis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Jesse Shefferman | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.16 per share. | 11 Jan 2021 | 5,069 | 835,205 (14%) | 0% | 21.2 | 107,260 | Common Stock |
| Jacqueline Zummo | Chf Scientific Operations Off | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.16 per share. | 11 Jan 2021 | 4,653 | 69,460 (1%) | 0% | 21.2 | 98,457 | Common Stock |
| Blaine Davis | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 16.91 per share. | 22 Sep 2020 | 1,481 | 1,481 (0%) | 0% | 16.9 | 25,038 | Common Stock |
| Barry P. Flannelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2020 | 8,250 | 26,250 | - | - | Stock Option (Right to Buy) | |
| Barry P. Flannelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2020 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Jesse Shefferman | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2020 | 111,250 | 111,250 | - | - | Stock Option (Right to Buy) | |
| Gregory P. Sargen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Luke M. Beshar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Roger J. Garceau | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Scott Braunstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Michael Edward Solomon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Blaine Davis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2020 | 94,000 | 94,000 | - | - | Stock Option (Right to Buy) | |
| Gregory P. Sargen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2020 | 31,000 | 31,000 (0%) | 0% | 0 | Common Stock | |
| Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2020 | 31,000 | 31,000 (0%) | 0% | 0 | Common Stock | |
| Luke M. Beshar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 6,676 | 6,676 | - | - | Stock Option (Right to Buy) | |
| Luke M. Beshar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 12,399 | 12,399 | - | - | Stock Option (Right to Buy) | |
| Roger J. Garceau | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 12,399 | 12,399 | - | - | Stock Option (Right to Buy) | |
| Scott Braunstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 15,641 | 15,641 | - | - | Stock Option (Right to Buy) | |
| Scott Braunstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 2,861 | 2,861 | - | - | Stock Option (Right to Buy) | |
| Scott Braunstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 16,214 | 16,214 | - | - | Stock Option (Right to Buy) | |
| Michael Edward Solomon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 26,500 | 26,500 (0%) | 0% | 0 | Common Stock | |
| Michael Edward Solomon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 2,861 | 2,861 | - | - | Stock Option (Right to Buy) | |
| Michael Edward Solomon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 6,676 | 6,676 | - | - | Stock Option (Right to Buy) | |
| Jesse Shefferman | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 111,250 | 111,250 | - | - | Stock Option (Right to Buy) | |
| Jacqueline Zummo | Sr. Vice President, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 28,613 | 28,613 (0%) | 0% | - | Common Stock | |
| Jacqueline Zummo | Sr. Vice President, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 45,500 | 74,113 (1%) | 0% | 0 | Common Stock | |
| Jacqueline Zummo | Sr. Vice President, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 9,537 | 9,537 | - | - | Stock Option (Right to Buy) | |
| Jacqueline Zummo | Sr. Vice President, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 9,537 | 9,537 | - | - | Stock Option (Right to Buy) | |
| Jacqueline Zummo | Sr. Vice President, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 19,075 | 19,075 | - | - | Stock Option (Right to Buy) | |
| Julio Casoy | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 38,151 | 38,151 | - | - | Stock Option (Right to Buy) | |
| Julio Casoy | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 45,500 | 45,500 (0%) | 1% | 0 | Common Stock |